How COVID-19 moved the needle on the visible value of diagnostics
From the laboratory to the layperson, from pathologists to the public, the response to in vitro diagnostic testing has been engaging across all sectors of society during the current pandemic. Chris Hudson provides a view on the reaction from Roche.
This story is Premium Content and is only available to registered users. Please log in to view the full text. If you don't already have an account, please register with us completely free of charge.